Form 4: STERIS Executive Sells Shares After Option Exercise

STERIS plc Senior VP Julia Madsen exercised stock options and subsequently sold a portion of her shares on November 21, 2025.

Summary

• Julia Madsen, Sr. VP and GM, Life Sciences at STERIS plc, engaged in multiple transactions on November 21, 2025.
• She exercised options to acquire 2,872 ordinary shares at a price of $114.22 per share.
• Concurrently, she sold 2,872 ordinary shares at a price of $262 per share.
• She also exercised options to acquire an additional 2,136 ordinary shares at a price of $147.05 per share.
• Simultaneously, she sold 2,136 ordinary shares at a price of $262 per share.
• Following these transactions, her direct beneficial ownership stands at 10,710 ordinary shares.
• Of these, 4,003 ordinary shares are restricted, with vesting scheduled between June 2026 and June 2028.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The filing indicates a routine, pre-planned insider transaction where an executive exercised options and sold shares for a profit, while still retaining a significant stake. This is generally a neutral to slightly positive event as it shows an executive realizing value from their compensation, often a sign of a healthy stock price, and the use of a 10b5-1 plan mitigates concerns about opportunistic selling.

Positives

• The executive realized a significant profit from exercising options at lower prices ($114.22 and $147.05) and selling shares at a higher market price ($262).
• The transactions were conducted under a Rule 10b5-1(c) plan, indicating pre-planned sales and reducing concerns about opportunistic insider trading.
• The executive retains a substantial number of shares (10,710), demonstrating continued alignment with shareholder interests.

Negatives

• The sale of 5,008 shares (2,872 + 2,136) by a Senior VP could be interpreted as a reduction in direct exposure to the company's stock, although it is part of a pre-planned option exercise and sale.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all industries for publicly traded companies. It reflects an executive's compensation realization rather than a strategic industry move.

Comparison to Industry Standards

• The use of Rule 10b5-1(c) plans for executive stock transactions is a standard corporate governance practice, aligning with best practices for managing insider trading concerns.
• The exercise of vested stock options and subsequent sale of shares is a common method for executives to realize value from their compensation packages, comparable to practices at peer companies in the medical technology and life sciences sectors such as Medtronic, Danaher, or Stryker.
• The retention of a significant number of shares post-transaction is also a common practice, indicating continued vested interest in the company's performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The executive's profitable sale of shares after exercising options could be viewed positively as a sign of value realization, but also as a slight reduction in direct insider ownership. The use of a 10b5-1 plan provides transparency.

Next Steps

• Monitoring future Form 4 filings for Julia Madsen or other STERIS plc executives to observe trends in insider buying or selling activity.
• Observing the lapse dates for the restricted shares to track changes in the executive's unrestricted beneficial ownership.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction involving the exercise of stock options and subsequent sale of shares by a Senior VP. While the executive realized a profit, these transactions are common for compensation and tax planning, especially when executed under a Rule 10b5-1 plan. The executive retains a substantial number of shares, indicating continued alignment. This type of filing typically does not signal a significant change in the company's fundamentals or strategic direction that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate, as the filing provides no new information to alter an existing investment thesis.

Keywords

STERIS plc, STE, Insider Trading, Form 4, Stock Options, Share Sale, Executive Compensation, Julia Madsen, Life Sciences, Beneficial Ownership